^
16h
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
|
Opdivo (nivolumab) • Estybon (rigosertib)
1d
FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
3d
Circulating tumor DNA
|
TMB (Tumor Mutational Burden)
4d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5d
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
5d
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
5d
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab) • adagrasib (MRTX849)
5d
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
5d
Clinical • FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
6d
HER-2 (Human epidermal growth factor receptor 2)
6d
Clinical • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
6d
Retrospective data • Review
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Imfinzi (durvalumab)
6d
Clinical
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
6d
RET (Ret Proto-Oncogene)
|
RET fusion
|
Gavreto (pralsetinib)
6d
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
6d
EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
6d
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • erlotinib
6d
EGFR (Epidermal growth factor receptor)
|
Avastin (bevacizumab) • Tagrisso (osimertinib)
7d
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
erlotinib • Enhertu (fam-trastuzumab deruxtecan-nxki) • poziotinib (HM 78136B)
8d
KRAS (KRAS proto-oncogene GTPase) • SOS1 (SOS Ras/Rac Guanine Nucleotide Exchange Factor 1)
8d
Clinical • Real-world evidence • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
8d
Clinical • Next-generation sequencing • Companion diagnostic • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib)
8d
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
BRAF V600E • BRAF V600 • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • Vectibix (panitumumab) • Lumakras (sotorasib) • adagrasib (MRTX849)
8d
FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
Clinical • Next-generation sequencing • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
Clinical • FDA event • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
9d
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
10d
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11)
|
TP53 mutation • KRAS mutation • STK11 mutation
10d
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TROP2 (Trophoblast Cell Surface Antigen 2)
10d
TROP2 (Trophoblast Cell Surface Antigen 2) • TFRC
|
telisotuzumab vedotin (ABBV-399) • datopotamab deruxtecan (DS-1062a) • CX-2029
11d
Preclinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
11d
Retrospective data • Review • Next-generation sequencing • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
12d
EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw)
13d
Clinical • FDA event • Breakthrough therapy designation • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • poziotinib (HM 78136B) • Exkivity (mobocertinib)
13d
Clinical • Next-generation sequencing • Endobronchial ultrasound
|
MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Opdivo (nivolumab)
13d
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation
13d
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
14d
Endobronchial ultrasound • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • NKX2-1 (NK2 Homeobox 1)
|
Guardant360® CDx
|
Tagrisso (osimertinib)
14d
Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Keytruda (pembrolizumab)
15d
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
15d
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
15d
Clinical • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
16d
Clinical • EGFR exon 20 • Patient reported outcomes
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
16d
EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
16d
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
16d
Clinical • P2 data
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
Tagrisso (osimertinib) • Kadcyla (ado-trastuzumab emtansine)
17d
Clinical
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • BRAF mutation
|
Mekinist (trametinib)
17d
EGFR (Epidermal growth factor receptor) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1)
|
EGFR expression
19d
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
20d
Review
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation